MedTrace Logo

QTX3046 in Patients With KRAS G12D Mutations

NCT06428500 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2025-07-25

No results posted yet for this study

Summary

Phase 1 study to determine the safety and tolerability of QTX3046 as a single agent or in combination with cetuximab.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

QTX3046

QTX3046 will be administered at protocol defined dose.

COMBINATION_PRODUCT

Cetuximab

Cetuximab will be administered at protocol defined dose.

Sponsors & Collaborators

  • Quanta Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-30
Primary Completion
2027-07-01
Completion
2027-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06428500 on ClinicalTrials.gov